Literature DB >> 33999555

ISUP Consensus Definition of Cribriform Pattern Prostate Cancer.

Theodorus H van der Kwast1, Geert J van Leenders, Daniel M Berney, Brett Delahunt, Andrew J Evans, Kenneth A Iczkowski, Jesse K McKenney, Jae Y Ro, Hemamali Samaratunga, John R Srigley, Toyo Tsuzuki, Murali Varma, Thomas M Wheeler, Lars Egevad.   

Abstract

The presence of a cribriform pattern is now recognized as a clinically important, independent adverse prognostic indicator for prostate cancer. For this reason the International Society of Urological Pathology (ISUP) recently recommended its inclusion in standard reporting. In order to improve interobserver agreement as to the diagnosis of cribriform patterns, the ISUP assembled an international panel of 12 expert urogenital pathologists for the purpose of drafting a consensus definition of cribriform pattern in prostate cancer, and provide their opinions on a set of 32 images and on potential diagnostic criteria. These images were selected by the 2 nonvoting convenors of the study and included the main categories where disagreement was anticipated. The Delphi method was applied to promote consensus among the 12 panelists in their review of the images during 2 initial rounds of the study. Following a virtual meeting, convened to discuss selected images and diagnostic criteria, the following definition for cribriform pattern in prostate cancer was approved: "A confluent sheet of contiguous malignant epithelial cells with multiple glandular lumina that are easily visible at low power (objective magnification ×10). There should be no intervening stroma or mucin separating individual or fused glandular structures" together with a set of explanatory notes. We believe this consensus definition to be practical and that it will facilitate reproducible recognition and reporting of this clinically important pattern commonly seen in prostate cancer. The images and the results of the final Delphi round are available at the ISUP website as an educational slide set (https://isupweb.org/isup/blog/slideshow/cribriform-slide-deck/).
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33999555     DOI: 10.1097/PAS.0000000000001728

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis.

Authors:  Giorgio Ivan Russo; Timo Soeterik; Ignacio Puche-Sanz; Giuseppe Broggi; Arturo Lo Giudice; Cosimo De Nunzio; Riccardo Lombardo; Giancarlo Marra; Giorgio Gandaglia
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-10-10       Impact factor: 5.455

2.  Predicting biochemical recurrence of prostate cancer with artificial intelligence.

Authors:  Hans Pinckaers; Jolique van Ipenburg; Jonathan Melamed; Angelo De Marzo; Elizabeth A Platz; Bram van Ginneken; Jeroen van der Laak; Geert Litjens
Journal:  Commun Med (Lond)       Date:  2022-06-08

3.  Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.

Authors:  L Lucia Rijstenberg; Tim Hansum; Charlotte F Kweldam; Intan P Kümmerlin; Sebastiaan Remmers; Monique J Roobol; Geert J L H van Leenders
Journal:  Histopathology       Date:  2022-05-04       Impact factor: 7.778

4.  Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.

Authors:  Emily Chan; Jesse K McKenney; Sarah Hawley; Dillon Corrigan; Heidi Auman; Lisa F Newcomb; Hilary D Boyer; Peter R Carroll; Matthew R Cooperberg; Eric Klein; Ladan Fazli; Martin E Gleave; Antonio Hurtado-Coll; Jeffry P Simko; Peter S Nelson; Ian M Thompson; Maria S Tretiakova; Dean Troyer; Lawrence D True; Funda Vakar-Lopez; Daniel W Lin; James D Brooks; Ziding Feng; Jane K Nguyen
Journal:  Mod Pathol       Date:  2022-02-10       Impact factor: 8.209

5.  Cribriform pattern disease over-represented in pelvic lymph node metastases identified on 68GA PSMA-PET/CT.

Authors:  Damien Bolton; Anne Hong; Nathan Papa; Marlon Perera; Brian Kelly; Catriona Duncan; David Clouston; Nathan Lawrentschuk
Journal:  BJUI Compass       Date:  2022-04-21

Review 6.  Cultivating Clinical Clarity through Computer Vision: A Current Perspective on Whole Slide Imaging and Artificial Intelligence.

Authors:  Ankush U Patel; Nada Shaker; Sambit Mohanty; Shivani Sharma; Shivam Gangal; Catarina Eloy; Anil V Parwani
Journal:  Diagnostics (Basel)       Date:  2022-07-22

7.  Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.

Authors:  Neslisah Seyrek; Eva Hollemans; Susanne Osanto; Rob C M Pelger; Henk G van der Poel; Elise Bekers; Chris H Bangma; John Rietbergen; Monique J Roobol; Ivo G Schoots; Geert J L H van Leenders
Journal:  Histopathology       Date:  2021-12-14       Impact factor: 7.778

Review 8.  WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.

Authors:  James G Kench; Mahul B Amin; Daniel M Berney; Eva M Compérat; Ian A Cree; Anthony J Gill; Arndt Hartmann; Santosh Menon; Holger Moch; George J Netto; Maria R Raspollini; Mark A Rubin; Puay Hoon Tan; Toyonori Tsuzuki; Samra Turjalic; Theo H van der Kwast; Ming Zhou; John R Srigley
Journal:  Histopathology       Date:  2022-08-02       Impact factor: 7.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.